Skip to main content
Clinical Trials/CTRI/2025/07/091159
CTRI/2025/07/091159
Not yet recruiting
Phase 2

Evaluation of efficacy of Moringa leaves extract in treatment of Oral Submucous Fibrosis in comparison with standard treatment protocol – A Randomised Controlled Trial

Dr Poonam Ambhore1 site in 1 country30 target enrollmentStarted: July 28, 2025Last updated:

Overview

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Dr Poonam Ambhore
Enrollment
30
Locations
1
Primary Endpoint
Change in clinical parameters (burning sensation, mouth opening, tongue protrusion, cheek flexibility)

Overview

Brief Summary

This pilot study aims to assess the efficacy of Moringa oleifera leaf extract in different forms (tablet, powder, and 4% gel) in the management of Oral Submucous Fibrosis (OSMF). A total of 30 clinically diagnosed patients will be randomly divided into three groups and treated for 30 days. Group I will receive Moringa tablets + SM-FIBRO + Moringa gel, Group II will receive Moringa powder + SM-FIBRO + Moringa gel, and Group III (control) will receive SM-FIBRO + Turbocort gel. Clinical improvements in burning sensation, mouth opening, tongue protrusion, and cheek flexibility will be evaluated at baseline, Day 10, Day 20, and Day 30, followed by a 1-month follow-up.

Study Design

Study Type
Interventional
Allocation
Coin toss, Lottery, toss of dice, shuffling cards etc
Masking
None

Eligibility Criteria

Ages
15.00 Year(s) to 45.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Clinically diagnosed OSMF Stage I to III by Khanna and Andrade classification
  • History of areca nut, gutkha, kharra, pan masala chewing
  • Willing to participate and give informed consent.

Exclusion Criteria

  • Habit cessation in the last 6 months
  • Stage IV OSMF
  • Systemic illness or medications
  • Allergy to Moringa or herbal drugs
  • Already undergoing treatment for OSMF.

Outcomes

Primary Outcomes

Change in clinical parameters (burning sensation, mouth opening, tongue protrusion, cheek flexibility)

Time Frame: from baseline to Day 30

Secondary Outcomes

  • Sustained improvement in symptoms at 1-month follow-up after treatment completion

Investigators

Sponsor
Dr Poonam Ambhore
Sponsor Class
Other [Self-funded postgraduate researcher]
Responsible Party
Principal Investigator
Principal Investigator

Dr Tapasya Karemore

Ranjeet Deshmukh Dental College and Research centre, Digdoh hills, Higna road, NAGPUR

Study Sites (1)

Loading locations...

Similar Trials